A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
Recruiting now · Phase 1/Phase 2
Conditions studied: Triple Negative Breast Cancer
In brief
The goal of this clinical study is to learn more about the study drug sacituzumab govitecan-hziy (SG) given at an alternative dose and schedule, in participants with triple-negative breast cancer (TNBC). The primary objectives of this study are to assess the safety and tolerability of SG given at alternate dose and schedule, to assess the effect on objective response rate (ORR) and progression-free survival (PFS).
Key facts
- Study ID
- NCT06926920
- Run by
- Gilead Sciences
- People needed
- 100
- Starts
- 2025-04-30
- Expected to finish
- 2028-06-01
- Last updated by the study team
- 2026-01-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Samsung Medical Center — Seoul, South Korea (enrolling)
- Winship Cancer Institute - Emory University — Atlanta, Georgia, United States (enrolling)
- The University of Kansas Hospital — Westwood, Kansas, United States (enrolling)
- Siteman Cancer Center — St Louis, Missouri, United States (enrolling)
- West Cancer Centre — Germantown, Tennessee, United States (enrolling)
- SCRI Oncology Partners — Nashville, Tennessee, United States (enrolling)
- Tennessee Oncology, PLLC — Nashville, Tennessee, United States (enrolling)
- Texas Oncology - DFW — Dallas, Texas, United States (enrolling)
- Virginia Oncology Associates — Norfolk, Virginia, United States (enrolling)
- St. Vincent's Hospital - Kinghorn Cancer Center — Darlinghurst, New South Wales, Australia (enrolling)
- Sunshine Coast University Private Hospital — Birtinya, Queensland, Australia (enrolling)
- John Flynn Private Hospital — Tugun, Queensland, Australia (enrolling)
- Seoul National University Hospital — Seoul, South Korea (enrolling)
- Los Angeles Cancer Network (LACN) - Good Sam — Los Angeles, California, United States (enrolling)
- Asan Medical Center — Seoul, South Korea (enrolling)
- Severance Hospital, Yonsei University Health System — Seoul, South Korea
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.